Meet In CommonNewsRSS feeds

Local

PharmaLogic buys Lantheus plant to build transatlantic radiopharmaceutical CDMO

Meet in Common connects news with real conversations. Use ThinkMatch to arrange a Roundtable and meet people to discuss this story.

Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.

Source: BioSpace

Less than two years after acquiring the assets, Lantheus is selling its CDMO unit and a New Jersey production plant to PharmaLogic. PharmaLogic has struck a deal to buy a radiopharmaceutical contract development and manufacturing organization (CDMO) and production plant from Lantheus. Lantheus acquired the CDMO and Springfield, New Jersey, production facility last year when it bought Evergreen Theragnostics for $250 million upfront. At the time, Lantheus hailed Evergreen's radioligand therapy manufacturing infrastructure and revenue-generating CDMO as a boost for its business. Yet, 19 months after closing the deal, Lantheus has agreed to offload the CDMO and New Jersey plant. PharmaLogic is buying the assets for an undisclosed sum to advance toward its goal of creating the first fully integrated, global CDMO specializing in radiopharmaceutical therapies.

This excerpt comes from the named source. Read the original for the full reporting.

Read the original at BioSpace

Featured places to meet in Springfield, NJ

Explore these places and arrange a conversation through ThinkMatch.

City guide for Springfield, NJ

Community Poll

Urgent public needs can justify simplifying normal approval procedures.

Share your view, then see how readers voted. No sign-in required. This poll is shared across stories.

Do you agree or disagree?

Choose one answer

Common Quandary

A Common Quandary to discuss

Another conversation to explore, separate from this news story.

A likable but unreliable former employee lists you as a reference. How honest are you?

A former employee who was unreliable but personally likable lists you as a reference without asking. Their prospective manager calls and asks only whether you would hire them again.

How much truth do you owe a stranger when it may cost someone a fresh start?

Explore this quandary